Home/Pipeline/PIPE-505

PIPE-505

Undisclosed

PreclinicalCandidate Selection

Key Facts

Indication

Undisclosed

Phase

Preclinical

Status

Candidate Selection

Company

Contineum Therapeutics

About Contineum Therapeutics

Contineum Therapeutics is a public, clinical-stage biotech (NASDAQ: CTNM) with a mission to develop oral, small molecule drugs for neuroinflammatory and fibrotic diseases. Its strategy leverages human genetic validation of specific GPCR targets, most notably the M1 muscarinic and LPA1 receptors, to derisk development and address large patient populations. Key achievements include advancing its lead asset, PIPE-307, to Phase 2 in multiple sclerosis and depression, and progressing a second key asset, PIPE-791, through Phase 1 for idiopathic pulmonary fibrosis and progressive MS. The company operates with a lean, virtual structure, utilizing strategic partnerships and CROs to advance its pipeline efficiently.

View full company profile

Therapeutic Areas

Neuroscience Immunology Inflammation

Other Undisclosed Drugs

Drug	Company	Phase	Status
Preclinical ISAC 1	Bolt Biotherapeutics	Preclinical	Available for Partnering
Preclinical ISAC 2	Bolt Biotherapeutics	Preclinical	Available for Partnering
ART12.11	Artelo Biosciences	Preclinical	Active
Novel Vaccines	MSD	Development	Active
SLS-009	Seelos Therapeutics	Discovery	Research
Measovir®-based Prophylactic Vaccine (with Unither)	Oncovita	Research/Pre-clinical	Early-stage collaboration
Internal sdAb Discovery Program	NanoTag Biotechnologies	Discovery	Active
Amgen Collaboration Program	Xeris Biopharma	Pre-clinical	Active
NB-701	Nerai Biosciences	Discovery	Active
Undisclosed Therapeutic Program(s)	Bright Cell	Clinical Trial (Phase unspecified)	Active
Biosimilars Pipeline	Intelligent Therapeutics	Pre-clinical/Development	Active
Proprietary Therapeutic Pipeline	Excelsior Sciences	Discovery	Active